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The achievement of optimal folate status to prevent neural-tube defects, and possibly other
diseases, is hindered by the well-recognised incomplete bioavailability of the natural folates
found in foods compared with the synthetic vitamin, folic acid. Folate bioavailability from
different foods is considered to be dependent on a number of factors, including the food matrix,
the intestinal deconjugation of polyglutamyl folates, the instability of certain labile folates
during digestion and the presence of certain dietary constituents that may enhance folate
stability during digestion. There is conflicting evidence as to whether the extent of conjugation
of polyglutamyl folate (in the absence of specific inhibitors of deconjugation in certain foods)
is a limiting factor in folate bioavailability. Estimates of the extent of lower bioavailability of
food folates compared with folic acid (relative bioavailability) show great variation, ranging
anywhere between 10 and 98%, depending on the methodological approach used. The lack of
accurate data on folate bioavailability from natural food sources is of particular concern in
those countries in which there is no mandatory folic acid fortification, and therefore a greater
reliance on natural food folates as a means to optimise status. Apart from the incomplete
bioavailability of food folates, the poor stability of folates in foods (particularly green
vegetables) under typical conditions of cooking can substantially reduce the amount of vitamin
ingested and thereby be an additional factor limiting the ability of food folates to enhance
folate status. A recent workshop convened by the Food Standards Agency concluded that
gaining a better understanding of folate bioavailability in representative human diets is a high
priority for future research.
Food folate: Folic acid: Folate bioavailability methodology: Folate requirements
Folate bioavailability refers to the proportion of ingested
folate that is absorbed and becomes available for metabolic
processes or storage. This B-vitamin has been attracting
major scientific and public health interest in recent years.
Apart from its well-established role in the prevention of
neural-tube defects (Medical Research Council Vitamin
Study Research Group, 1991; Czeizel & Dudas, 1992),
newer potential roles for folate in protecting against CVD
(Wald et al. 2002; Strain et al. 2004), certain cancers
(Choi & Mason, 2000) and neuro-psychiatric conditions
(Seshadri et al. 2002) are emerging. However, when
dietary intakes are viewed from the perspective of
optimising folate status to levels associated with lowest
risk of disease, rather than merely preventing overt folate
deficiency (i.e. megaloblastic anaemia), it is clear that
typical folate intakes are suboptimal in the diets of many
individuals. This widespread under-provision of folate is
generally attributed to the poor bioavailability of natural
food folates. Although there is general agreement among
experts that the bioavailability of natural food folates is
incomplete when compared with the synthetic vitamin,
folic acid (FA), the extent to which bioavailability is
reduced is somewhat controversial. Estimates of the extent
of lower bioavailability of food folates compared with FA
(relative bioavailability) show great variation in human
studies, ranging anywhere between 10 and 98% (Tamura
& Stokstad, 1973; Coleman et al. 1975; Baker et al. 1978;
Sauberlich et al. 1987; Brouwer et al. 1999; Prinz-
Langenohl et al. 1999).
As a result of the major current focus and debate on FA
fortification of foods, the issue of incomplete bioavail-
ability of natural folates may be considered unimportant.
Abbreviations: DFE, dietary folate equivalents; FA, folic acid; GCPII, glutamate carboxypeptidase II.
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However, it remains a fundamental concern for two
reasons. First, there are many countries that do not have
legislation in place for the mandatory fortification of grain
food with FA similar to that introduced in recent years in
North America (Fletcher et al. 2004). Such countries are
therefore reliant mainly on natural food folates as a means
to optimise status. Second, irrespective of whether a
country has a FA fortification policy, the issue of setting
dietary folate recommendations remains an ongoing con-
cern for policy makers. The focus here has generally
shifted in recent years from the traditional approach of
preventing overt deficiency to the newer evidence-based
approach of setting dietary requirements on the basis of
optimal health. However, in the case of folate, recommen-
dations based on an adjustment for the differences in
bioavailability between natural food folates and the
synthetic vitamin are emerging, with the recent introduc-
tion of ‘dietary folate equivalents’ (DFE; Institute of
Medicine, 1998) in the USA. The DFE is defined as the
quantity of natural food folate plus 1.7 times the quantity
of FA in the diet; this definition is based on the assumption
that the bioavailability of FA added to food is greater
than that of natural food folate by a factor of 1.7. This
estimation is, however, highly dependent on one metabolic
study in non-pregnant women that estimated the bioavail-
ability of food folates to be £50% relative to that of FA
(Sauberlich et al. 1987), and other evidence showing that
FA added to food has about 85% of the bioavailability of
free FA (Pfeiffer et al. 1997). Other countries wishing to
consider the use of this approach or a similar one for
setting dietary folate recommendations require accurate
and meaningful folate bioavailability data in order to
confirm the robustness of the US DFE value.
The present review will address the various factors that
are considered to contribute to the incomplete bioavail-
ability of natural folates from foods, the experimental
approaches that have been used to examine food folate
bioavailability, the major findings from recent bioavail-
ability studies in human subjects and future research
priorities.
Factors considered to contribute to the incomplete
bioavailability of natural food folates
The bioavailability of folates from various foods is
considered to be dependent on a number of factors,
including: intestinal deconjugation of polyglutamyl folates;
the food matrix; the instability of certain labile folates
during digestion (or before ingestion); the presence of
certain dietary constituents that may enhance folate
stability during digestion (e.g. folate-binding proteins,
ascorbate).
Factors related to intestinal deconjugation of food folates
In contrast to synthetic FA, which is a monoglutamate,
natural food folates are predominantly polyglutamates with
a variable number of glutamate residues. A recent study
from The Netherlands has estimated that approximately
two-thirds of total folate intake from a mixed unfortified
diet is in the polyglutamyl form, derived mainly from
vegetables (Melse-Boonstra et al. 2002). These polygluta-
mates need to be hydrolysed to the monoglutamate form
for normal absorption in the proximal small intestine. This
process is controlled by the intestinal brush-border enzyme
glutamate carboxypeptidase II (GCPII).
GCPII has a pH optimum at 6–7 (Halsted, 1990) and
ingestion of foods that can change the intestinal pH may
result in incomplete intestinal deconjugation of polygluta-
myl folates. For example, Tamura et al. (1976) have found
a marked reduction in the bioavailability of heptaglutamate
when added to 600 ml diluted orange juice in comparison
with FA. The authors have established that the reduction in
heptaglutamate bioavailability is as a result of the lowering
of pH (to 3.7) by the high load of orange juice. They have
shown that heptaglutamate bioavailability is reduced when
citric acid is added to orange juice, but when the same
mixture is neutralised to pH 6.4 the bioavailability of
heptaglutamate does not differ from that of FA (Tamura
et al. 1976). In addition, some food components and
certain drugs have been reported to act as inhibitors of the
activity of GCPII. Studies with stable isotopes in human
subjects (Wei et al. 1996) and in vitro experiments with
porcine jejunal brush-border membrane (Wei & Gregory,
1998) indicate that organic acid ions (citrate, malate,
ascorbate and phytate) present in orange juice have a
combined inhibitory effect on the activity of GCPII.
Nucleic acids in yeast ingested in large doses have also
been reported to decrease the activity of GCPII (Rosenberg
& Godwin, 1971). A naturally-occurring heat-activated
GCPII inhibitor has been identified in the skin of various
pulses (Butterworth et al. 1974); however, later bioavail-
ability studies with human subjects have failed to detect
any effect of beans on the utilisation of heptaglutamates
(Keagy et al. 1988). Some drugs (salicylazosulfapyridine)
and ethanol have also been reported to competitively
inhibit GCPII (Halsted, 1990).
Recently, a polymorphism (C1561T) in the gene
encoding GCPII has been identified and in vitro studies
have found that COS-7 cells expressing the mutant variant
have a 53% lower GCPII enzyme activity than cells with
the wild genotype (Devlin et al. 2000). However, the
frequency of the homozygous mutant genotype for this
polymorphism in the general population is very low
(0.5%), and its in vivo effects on dietary folate digestion
and folate status remain unclear, since various human
studies have shown contradictory results (Devlin et al.
2000; Lievers et al. 2002; Vargas-Martinez et al. 2002;
Afman et al. 2003).
The question as to whether polyglutamyl folates are
inherently less bioavailable than monoglutamyl folates (i.e.
in the absence of specific inhibitors of deconjugation such
as organic acids) remains to be resolved. The bioavail-
ability of folate polyglutamates relative to monoglutamates
has been explored in different studies with various results.
Earlier acute studies (Godwin & Rosenberg, 1975; Keagy
et al. 1988), together with a recent chronic study by Melse-
Boonstra et al. (2004), have indicated that the bioavail-
ability of polyglutamyl folate is markedly lower than
that of monoglutamyl folate. In contrast, recent results
(Hannon-Fletcher et al. 2004) have found no evidence to
support the view that the extent of glutamation per se is a
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limiting factor in the bioavailability of folates from natural
food sources. A 6-week intervention study with healthy
subjects has shown no difference in the bioavailability of
folates from yeast (providing 100% of the folate as
polyglutamyl folate) and spinach (Spinacia oleracea;
providing 50% of the folate as polyglutamyl folate). These
observations are in good agreement with previous findings
(Wei et al. 1996) from studies using exogenous 2H-
labelled monoglutamyl and polyglutamyl folates added to
various foods that have shown equivalent bioavailability
for the two forms of folate. Similar findings have also been
reported by Konings et al. (2002) in an acute study of
subjects with an ileostomy that compared folate absorption
from spinach containing 60% of the folate as polygluta-
mate and spinach pretreated before ingestion to convert the
folates to the monoglutamate form. All such findings
showing a similar bioavailability for polyglutamyl and
monoglutamyl folate forms are consistent with earlier
observations (Halsted, 1990) indicting that the activity of
the human jejunal brush-border enzyme GCPII exceeds
that needed for hydrolysis of polyglutamyl folates within
the range of dietary intake and is, therefore, not rate
limiting in the absorption process.
Factors related to the food matrix
Since folates are covalently bound to macromolecules in
foods, the food matrix as a whole and its components can
also influence folate bioavailability by entrapment in the
matrix, thereby hindering diffusion to the absorptive
surface during digestion. Incomplete release from plant
cellular structure may be a factor affecting folate bioavail-
ability in certain plants. Two independent studies have
demonstrated that folate bioavailability from minced,
chopped or enzymically-liquefied spinach is higher than
that from whole spinach leaves when equal amounts of
spinach folates are provided to human volunteers (van het
Hof et al. 1999; Castenmiller et al. 2000). The effects of
wheat bran and dietary fibre on folate bioavailability have
been explored in various acute and longer-term studies in
human subjects, but the results are inconsistent (Bailey
et al. 1988; Keagy et al. 1988; Castenmiller et al. 2000).
In vitro studies with intestinal brush-border-membrane
vesicles have indicated that dietary fibre does not affect the
activity of GCPII (Bhandari & Gregory, 1990).
Factors related to chemical instability of food folates
Unlike FA, which is a fully-oxidised molecule, natural
folates are a mixture of reduced forms with or without C1
substitution of the pteridine ring. The chemical structure of
FA renders it very stable to oxidation and resistant to
destruction (Colman et al. 1975), whereas natural folates
are labile and prone to oxidative cleavage at the C-9–N-10
bond (Murphy et al. 1976). There are two consequences in
relation to folate availability. First, extensive losses of
folate can occur during cooking and preparation of foods,
which may considerably reduce the amount of folate
ingested. Folate losses in the range of 50–80% have been
reported in green vegetables after boiling (Hurdle et al.
1968; Leichter et al. 1978; De Souza & Eitenmiller, 1986;
McKillop et al. 2002) and in processed legumes (Dang
et al. 2000). In addition to any folate losses before
ingestion, considerable instability of certain labile food
folates has been demonstrated in studies in vitro that
mimick the intestinal digestion of folates from various
foods (Seyom & Selhub. 1998). Thus, the instability of
labile folate species in vivo may be an important factor
contributing to the incomplete bioavailability of natural
food folates.
As indicated by previous studies (Smith et al. 1985;
Andersson & Oste, 1992), some dietary constituents may
enhance folate bioavailability by increasing the stability of
food folates during food processing and during digestion in
the gastrointestinal tract (e.g. folate-binding protein and
antioxidants such as ascorbic acid).
Other potential factors affecting food folate bioavailability
Apart from potential factors affecting intestinal deconjuga-
tion, food matrix effects or chemical instability of food
folates, the presence of other food components in the
intestinal milieu may inhibit folate absorption. For
example, Pfeiffer et al. (1997) have reported a small
reduction in the absorption of [13C-5]FA when it is
administered after a light breakfast meal compared with
its administration without food.
Experimental approaches to determining food folate
bioavailabililty
The bioavailability of natural folates has been studied
using various acute and chronic protocols that involve the
administration of reduced folates either in the form of
foods or commercial preparations corresponding to the
major food folate forms (usually 5-methyltetrahydro-
folate). Typically the bioavailability of reduced folates is
compared with that of FA, since the latter, which is the
form used for supplementation and food fortification
purposes, is considered to be highly bioavailable.
Acute studies
The protocol used in acute folate bioavailability studies is
similar to that employed in pharmacology for testing the
pharmacokinetics of different drugs. Typically, in a cross-
over or parallel design, a single ingestion of a reference
dose of reduced folates or FA is administered to human
volunteers and the changes in blood and/or urinary folate
concentrations are monitored at various time points. The
typical variables used to compare responses between the
different treatments include the maximal plasma or serum
folate concentration, the time required to achieve maximal
plasma or serum folate response, the calculated area under
the curve for plasma or serum folate response and urinary
folate measurements. On the basis of the type of folate
compounds administered, acute studies may be subdivided
into two categories, non-isotopic and isotopic studies.
Non-isotopic acute studies. The important methodologi-
cal considerations of non-isotopic acute studies have
been discussed comprehensively by other investigators
(Pietrzik et al. 1990; Gregory, 1995, 2001). These
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considerations include: the administration of a folate dose
sufficiently high to elicit measurable folate responses in
blood or urine, but not so high that it exceeds the
physiologically-relevant range; the selection of subjects
with high folate status or the use of a folate presaturation
protocol (otherwise the ingested dose may be preferentially
directed towards depleted folate pools); frequent and
substantial length (usually at least 8 h) of monitoring of
the folate response after ingestion of the test dose in order
to ensure that the peak response is not missed and to allow
sufficient time for folate concentrations to return to
baseline values; the recruitment of a sufficient number of
subjects for statistical power, given the variability in the
folate response; the avoidance of fasting, which is reported
to provoke an increase in plasma folate levels, probably by
interrupting the enterohepatic folate circulation; strict
control of dietary folate intake during the treatment period;
the inclusion of a placebo group to control for any changes
in folate measurements as a result of the conditions of the
protocol.
The earliest non-isotopic acute studies using folate
compounds in the physiological range of intake reported
a variety of results. Perry & Chanarin (1970) and Brown
et al. (1973) demonstrated higher serum responses to
reduced folates than to FA, whereas Tamura & Stokstad
(1973) were unable to show any marked differences
between natural folate forms and FA, based on 24 h
urinary folate excretion. However, the validity of these
early results is questionable, given the lack of placebo
treatment in any of the studies and, particularly, the short
period of monitoring (2–3 h), which was insufficient to
quantify the full plasma folate response in the studies of
Perry & Chanarin (1970 and Brown et al. (1973). A later
acute study, using a very extended period of blood folate
monitoring (3 d) and a higher folate dose (1000mg), has
reported similar bioavailabilities for 5-formyltetrahydro-
folate and FA, based on the area under the curve for plasma
folate response (Pietrzik & Remer, 1989). Such findings
are in agreement with a recently published study (Pentieva
et al. 2004) showing equivalent bioavailabilities for 5-
methyltetrahydrofolate and FA, based on plasma folate
response measured for a 10 h period and using a much
lower folate dose of 500mg.
Few studies have explored folate bioavailability from
different foods in an acute model. Tamura & Stokstad
(1973) have reported that folate bioavailability, measured
by urinary folate excretion up to 24 h after the food
consumption, varies considerably between different foods.
Twelve food items were studied, of which banana and lima
beans (Phaseolus limensis) were found to contain highly-
bioavailable folates (82–96% relative to FA), whereas
folates from other foods such as romaine lettuce, orange
juice, cabbage, soybean meal and wheat germ have a low
bioavailability (25–47%). More-recent studies, based on the
determination of serum folate area under the curve, have
reported that the bioavailability of folates from wheat-
aleurone flour (Fenech et al. 1999) and from spinach
(Konings et al. 2002) is similar to that of an equivalent
amount FA provided as a tablet. The reported differences
between studies in the bioavailability of folates from
various foods are probably the result of differences in the
protocols used, together with any inherent differences
between the foods administered, including the food
matrices and other potential factors affecting folate
bioavailability (GCPII inhibitors, pH).
Isotopic acute studies. Isotopic studies offer the advan-
tage of high specificity, since the only source of the
labelled folate detected in the blood and/or urine can be the
ingested folate isotope (Gregory, 2001). These studies
became particularly attractive after the introduction of
stable-isotope folate forms considered safe for human use.
However, the measurement of the labelled folates and their
metabolic products requires expensive and sophisticated
equipment such as GC–MS or liquid chromatography–MS.
In addition, most of the stable-isotope folates are not
commercially available and need to be synthesised and
purified by the investigators (Gregory, 1990; Maunder et al.
1999). Other investigators (Gregory & Toth, 1990;
Gregory & Quinlivan, 2002) have reviewed the method-
ological requirements for stable-isotope folate studies. Two
types of protocols have been used: (1) single-tracer
protocols involving the monitoring of plasma folate
responses after the administration of an oral dose of
labelled reduced folates or FA (Wright et al. 2003); (2)
dual-tracer protocols in which urinary isotope excretion
ratios are compared after an oral dose of labelled reduced
folates or FA and an intravenous dose of differently-
labelled FA (Gregory et al. 1992). In general, studies using
both types of protocols have tended to suggest differential
bioavailability of FA compared with reduced folate
derivatives. However, recent isotopic studies by Wright
et al. (2003) and Sanderson et al. (2003) have raised
questions about the interpretation of results from acute
bioavailability protocols that rely on measuring responses
to the oral administration of various folates relative to a
reference dose of FA. These authors have examined the
rate and extent of appearance of labelled and unlabelled
folates in plasma following oral doses of FA, 5-formyl-
tetrahydrofolate or intrinsically-labelled spinach folates.
The results show a marked difference in the absorption of
FA v. the natural folates; however, all forms cause an
increase in unlabelled plasma folate, and the extent of this
phenomenon differs between FA and the natural folates.
The authors concluded that there is a different hepatic first-
pass effect between FA and the reduced folate forms, and
highlighted a potential limitation with this approach arising
from the displacement of unlabelled tissue folate (not
originating from the oral test doses) into the plasma. Other
potential limitations of this (Wright et al. 2003) and
similar studies that may constrain their interpretation
include the administration of the folate treatments at
different doses, with subsequent mathematical adjustment
of the response to an equivalent dose, and the fasting of
subjects for >16 h, which may provoke an increase in
unlabelled plasma folate by diminishing bile secretion into
the gut, reported to be a major elimination route for folates
(Pietrzik et al. 1990).
Chronic studies
Chronic bioavailability studies explore, usually in parallel
design, the effect of long-term (typically 4–24 weeks)
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interventions with comparable doses of FA and reduced
folates (specific food folates, mixed diets or commercial
preparations corresponding to the major food folate forms)
on markers of folate status (serum folate, erythrocyte
folate, plasma homocysteine). To avoid the effect of
confounding factors on the response measurement, the
following categories of subjects should be excluded from
participation: users of B-vitamin supplements; users of
drugs affecting B-vitamin metabolism; those suffering
from chronic disease. The inclusion of a placebo group is
essential to control for any changes in folate measurements
as a result of the conditions of the intervention. In order
to accurately compare the effects of different treatments,
it is important that subjects are stratified at baseline to
the various treatment groups on the basis of an end point
of interest, particularly if (as in the case of plasma
homocysteine) the response is likely to be influenced by
baseline values. In addition, subject compliance to the
intervention needs to be rigorously supervised by frequent
contacts and recorded on an ongoing basis during the
intervention period. Furthermore, the total folate content in
the treatments being administered needs to be verified at
the start and during the intervention. These aspects are
often overlooked in the reporting of chronic folate
bioavailability studies, but are of major relevance in the
interpretation of the results. If these measures are not in
place to confirm that the targetted folate levels are being
delivered over the intervention period, any comparison of
responses to different folate treatments or different
intervention doses will be very problematic.
Studies examining the effect of chronic supplementation
with commercial folate preparations at doses in the range
of 100–400mg/d have reported similar bioavailabilities for
FA and 5-methyltetrahydrofolate (Venn et al. 2002, 2003;
Lamers et al. 2004). However, the results of chronic
studies using food folates to estimate the bioavailability of
natural folates relative to FA show great variation
depending on the food source and the response index
used. The interpretation of bioavailability studies involving
the provision of folate-rich foods to free-living subjects
may be particularly problematic as a result of a number of
confounding effects. These effects include the poor
stability of food folates during cooking (McKillop et al.
2002), which results in considerable and very variable
folate losses before ingestion. This factor, together with
poor compliance of subjects with demanding intervention
protocols in long-term studies or dietary displacement of
usual food folate sources with intervention foods (Cuskelly
et al. 1996; Ashfield-Watt et al. 2003), may result in
considerably less food folate being consumed than that
targetted. In contrast, FA treatment, against which
responses to food folates are typically compared, not only
provides the vitamin in a very stable form, but it is likely
to be associated with much greater compliance of subjects
because they are required to simply ingest a tablet daily in
addition to their usual diet (Cuskelly et al. 1996). Such
differences can exert major confounding effects that
compromise the interpretation of many folate bioavail-
ability studies in human subjects.
One landmark study, which measured non-pregnant
women for 92 d in a metabolic unit, estimated the
bioavailability of natural folates from a mixed diet to be
£50% that of FA (Sauberlich et al. 1987). Although this
study was very precise, the results are based on a small
number of subjects (ten subjects divided into three parallel
groups) and have never been confirmed in a larger-scale
metabolic study. However, in the absence of a more
reliable estimate, the results of the Sauberlich et al. (1987)
study have been used as the basis to set current US dietary
folate recommendations, which are now expressed as DFE
values (Institute of Medicine, 1998). The concept of DFE
recognises for the first time the differences in bioavail-
ability between natural food folates and the synthetic
vitamin FA that is added to foods during fortification.
Recent results (Hannon-Fletcher et al. 2004), based on the
administration of representative food folates in a controlled
(but not metabolic) 6-week intervention study, have
estimated the bioavailability of food folate relative to FA
to be approximately 45%, consistent with the estimate of
‘ < 50%’ (Sauberlich et al. 1987) used as the cornerstone
of the US DFE value. Also generally consistent with the
US approach, chronic studies in free-living subjects that
have compared the response of food folates with that of
FA-fortified foods at equivalent intakes have shown the
latter to be much more effective in increasing serum and
erythrocyte folate (Cuskelly et al. 1996; Riddel et al. 2000)
and reducing homocysteine (Riddel et al. 2000).
Recent folate bioavailability studies and future
research priorities
The Food Standards Agency recently convened a work-
shop to review current research and to consider future
research priorities in folate bioavailability. The full report,
which includes the results of a number of recently-
completed studies (many of which were Food Standards
Agency funded), has been published elsewhere (Sanderson
et al. 2003). The workshop concluded that the assessment
of folate bioavailability in whole diets is a high priority for
future research.
The biggest challenge in any future studies aiming to
assess folate bioavailability in this way will be the delivery
of food folate and FA at equivalent doses throughout the
intervention period. One way in which the whole diet
could be controlled would be to conduct the study in a
metabolic unit. However, this approach in itself will not
guarantee that the folate content of the administered foods
is equivalent to the FA dose being administered in parallel.
In order to ensure equivalence all meals and snacks for the
intervention period (whether or not it is conducted in a
metabolic unit) would need to be prepared and analysed
before they are consumed. The alternative, verifying the
folate content of the intervention diet after its administra-
tion (by duplicate meal analysis, for example), has proven
to be problematic even in highly-controlled studies such
as that of Brouwer et al. (1999), because analysis of
administered foods often reveals folate levels not equiva-
lent to the FA dose, necessitating the use of a correction
factor at the analysis stage. The major reason why the
amount of folates in a meal is often found on analysis to
differ from that targetted is primarily a result of the well-
documented underestimation of the folate content of foods
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in current Food Tables. Using newer food folate method-
ology based on trienzyme (protease, amylase and con-
jugase) treatment (Tamura et al. 1997), much higher
values have been reported recently for folates in various
plant and animal foods and in composite meals (McKillop
et al. 2002; Pentieva et al. 2002) compared with published
folate values generated using traditional folate method-
ology. This finding, if confirmed, may have major implica-
tions for the calculation of dietary folate intake (and
therefore folate recommendations) and requires further
investigation.
Conclusions
Food folate bioavailability and the factors that affect it are
poorly understood. These considerations are important,
given the established and emerging roles for folate in
disease prevention on the one hand, and the widespread
under-provision of folate in typical diets in most European
countries on the other. A number of methodological
approaches have been used to address food folate
bioavailability, but there are some major limitations that
may confound the interpretation of studies using these
various approaches. Chronic studies with food folates are
likely to give the most meaningful results in future
research, but only if they are based on robust and tightly-
controlled protocols to ensure the delivery of food folate
and FA at equivalent doses throughout the intervention
period. This challenge is a considerable one if folate
bioavailability in whole diets is to be accurately assessed
in order to provide quantifiable data on which to base food
policy. In addition to the incomplete bioavailability of food
folates generally evident from the literature, the poor
stability of food folates (particularly in green vegetables)
during cooking is an additional factor contributing to the
limited ability of natural food folates to optimise folate
status.
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